Clinical Study | Office of Clinical Research

Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Comparing 3 Mg And 12 Mg Of Ly3202626 With Placebo Over 52 Weeks In Approxima

Posted Date: May 15, 2019

Investigator: Lawrence Goldstick
Type of Study: Drug

This study is being done to see how safe a new investigational drug is and how well it might work to help people with Alzheimer?s disease. ?Investigational? means that the drug being tested has not been approved for sale or routine clinical use in the United States by the U.S. Food and Drug Admin

Criteria:

You Cannot Be In This Study If: ? You Have Certain Neurologic Diseases Or Psychiatric Disorders. ?

Keywords:

Dementia, Eli Lilly, Alzheimer?S Disease, Ly3202626

For More Information:

Samantha Maldonado
(937) 535-5012
samantha.maldonado@uchealth.com

Name*
First Last
Gender*
- Male
- Female
Age*
Phone*
Email*
How did you hear about us?*
Future Communication*
- By submitting this form, I am agreeing to receive future communication about participating in an upcoming research study.
CAPTCHA
This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.
List